TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607371

Intervention type: OTHER
Intervention: VKAs
Description: VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: OTHER
Intervention: NOACs including Rivaroxaban (Xarelto, BAY59-7939)
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: OTHER
Intervention: Edoxaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: OTHER
Intervention: Apixaban
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)

Intervention type: OTHER
Intervention: Dabigatran-etexilate
Description: NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
Study: NCT00800280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Single 300 mg dose of PD 0332334 immediate release capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cimetidine
Description: 600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
Study: NCT03771196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioactive Restorative Material
Description: enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin-modified glass ionomer
Description: Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
Study: NCT01996358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,3
Description: General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,6
Description: General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
Study: NCT04706533

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers of inflammation
Description: Biomarkers were measured on blood samples collected within 48 hours of admission
Study: NCT03670056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination immunotherapy with Ipilimumab and Nivolumab
Description: Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
Study: NCT00612534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab
Description: 5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NanoTab
Description: Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab
Description: 10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study: NCT02805036

Intervention type: DEVICE
Intervention: echocardiography
Description: • Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).

Intervention type: DEVICE
Intervention: echocardiography
Description: • Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).

Intervention type: DEVICE
Intervention: Arterial oximetry
Description: measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care

Intervention type: DEVICE
Intervention: Arterial oximetry
Description: measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
Study: NCT02536885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal group
Description: If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive group
Description: If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
Study: NCT04656860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus+
Description: Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
Study: NCT00839527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match albiglutide
Description: albiglutide matching placebo weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match albiglutide
Description: albiglutide matching placebo weekly subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection
Study: NCT01667367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: Single oral dose
Study: NCT00839527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride
Study: NCT04656860

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice Plus+
Description: Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
Study: NCT00839527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match pioglitazone
Description: pioglitazone matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to match pioglitazone
Description: pioglitazone matching placebo
Study: NCT01667367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral dose
Study: NCT03115138

Intervention type: OTHER
Group type: OTHER
Intervention: Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
Description: The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
Study: NCT01782417

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: patient and provider intervention
Description: Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
Study: NCT02179970

Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
Study: NCT00584402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perflutren lipid microspheres
Description: perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
Study: NCT04540796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75348780
Description: Participants will receive JNJ-75348780 by subcutaneous (SC) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75348780
Description: Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
Study: NCT01336621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine IR
Description: Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
Study: NCT03967002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group with corticotomy surgery
Description: The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~* the second premolars and first premolars,~* the first lower premolars and canines,~* the canines and lateral incisors,~* the lateral incisors and central incisors, and,~* the two lower central incisors.
Study: NCT03051685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Study: NCT01712880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open debridement with modular exchange

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one stage exchange
Study: NCT04469738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is functioning
Study: NCT02579096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol capsule, 100-800 mg by mouth once daily
Description: Patients will be up-titrated up to the dose required to reach target uric acid levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablet 40-120 mg by mouth once daily
Description: Patients will be up-titrated to the dose required to reach target uric acid levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, vehicle control (febuxostat-shaped)
Description: Placebo tablets resembling febuxostat will be given with allopurinol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, vehicle control (allopurinol-shaped)
Description: Placebo capsules resembling allopurinol will be given with febuxostat.
Study: NCT03650582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Intranasal glucagon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo
Study: NCT00980603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin
Description: docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, S-1
Description: docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
Study: NCT01576588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
Study: NCT03002649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
Study: NCT03847558

Intervention type: DIAGNOSTIC_TEST
Intervention: FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males
Description: assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
Study: NCT03561506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
Study: NCT03556371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
Study: NCT02494726

Intervention type: OTHER
Intervention: Thromboelastography
Description: TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.

Intervention type: OTHER
Intervention: Thromboelastography
Description: TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.

Intervention type: OTHER
Intervention: Thromboelastography
Description: TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
Study: NCT03348709

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoosmolar
Description: 48 hours, 800 ml per 24 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperosmolar
Description: 48 hours, 800 ml per 24 hours
Study: NCT01911585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
Study: NCT01851070

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Mesenchymal Precursor Cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study: NCT02848703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phosphorus-31 Magnetic Resonance Spectroscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium-23 MRI